CBER Director Notes FY 2018 Accomplishments, Including Approval of Two Gene Therapies

Looking back over the past fiscal year, Peter Marks, director for Center For Biologics Evaluation And Research (CBER) at the U.S. Food and Drug Administration (FDA), said 2018 was productive and exciting as the FDA department continued to support the advancement of 21st-century medicine.